top of page
Browse by category
Search
CagriSema associated with significant reduction in blood pressure and reduces the proportion of patients at risk of developing heart disease
Post hoc analyses from the phase 3 REDEFINE 1 trial evaluating CagriSema, an investigational injectable combination treatment for adults with overweight or obesity, and its effects on well-known cardiovascular (CV) risk factors, has revealed that systolic blood pressure was reduced by -10.9 mmHg over 68 weeks (versus -8.8 mmHg with semaglutide 2.4 mg and -2.1 mmHg with placebo). This reduction was seen regardless of BMI (less than versus greater than or equal to 35 kg/m2). In
REDEFINE 1 trial: CagriSema results in 22.7% mean weight reduction in adults with overweight or obesity
Outcomes from Novo Nordisk's phase 3 REDEFINE 1 trial - evaluating the efficacy and safety of investigational CagriSema plus lifestyle...
REDEFINE 2: CagriSema demonstrates superior weight loss
Outcomes from the from REDEFINE 2, a phase 3 trial in the global REDEFINE programme, have revealed the trial achieved its primary...
REDEFINE 1 trial: CagriSema demonstrates superior weight loss in adults with obesity or overweight
Headline results from Novo Nordisk’s REDEFINE 1 has shown that the trial achieved its primary endpoint by demonstrating a statistically...
Novo Nordisk to initiate study assessing CagriSema vs Tirzepatide
Novo Nordisk is planning a study that will see CagriSema, a new investigational medicine developed by Novo that combines Cagrilintide and...
Browse by tag
bottom of page